: Viridian stock falls more than 15% after drug study update
Shares of Viridian Therapeutics Inc. VRDN fell in the extended session Monday after the biotech drug maker said it was making changes to its study design for a chronic thyroid eye disease therapy. Viridian shares fell more than 17% after hours, following a 5.1% rise to close the regular session at $24.52. The company said it will only follow a five-dose treatment of its drug candidate VRDN-001 compared with a placebo, dropping the study of an eight-dose treatment, following discussions with the Food and Drug Administration. The company said it plans to begin the late-stage study in the third quarter of 2023, with topline results coming out in the middle of 2024.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.